Search Result

Isoforms Recommended:	P2Y12 Receptor

Results for "

P2Y12 receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (1) Arrestin (1) Biochemical Assay Reagents (1) Calcium Channel (1) Caspase (2) CD73 (1) Drug Derivative (1) Drug Metabolite (6) ERK (2) Estrogen Receptor/ERR (1) Ferroptosis (1) FXR (1) G protein-coupled Bile Acid Receptor 1 (1) Glutathione Reductase (GR) (1) Interleukin Related (2) Isotope-Labeled Compounds (7) MEK (1) mTOR (1) NF-κB (2) NTPDase (1) P2Y Receptor (53) p38 MAPK (1) Phosphodiesterase (PDE) (1) PI3K (1) PKA (1) Raf (1) Reference Standards (5) Transmembrane Glycoprotein (1)
By Research Areas:	Cancer (10) Cardiovascular Disease (44) Inflammation/Immunology (13) Metabolic Disease (1) Neurological Disease (7)

By Targets:

Akt (1)

Apoptosis (1)

Arrestin (1)

Biochemical Assay Reagents (1)

Calcium Channel (1)

Caspase (2)

CD73 (1)

Drug Derivative (1)

Drug Metabolite (6)

ERK (2)

Estrogen Receptor/ERR (1)

Ferroptosis (1)

FXR (1)

G protein-coupled Bile Acid Receptor 1 (1)

Glutathione Reductase (GR) (1)

Interleukin Related (2)

Isotope-Labeled Compounds (7)

MEK (1)

mTOR (1)

NF-κB (2)

NTPDase (1)

P2Y Receptor (53)

p38 MAPK (1)

Phosphodiesterase (PDE) (1)

PI3K (1)

PKA (1)

Raf (1)

Reference Standards (5)

Transmembrane Glycoprotein (1)

By Research Areas:

Cancer (10)

Cardiovascular Disease (44)

Inflammation/Immunology (13)

Metabolic Disease (1)

Neurological Disease (7)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10064

Ticagrelor 10+ Cited Publications AZD6140; AR-C 126532XX	P2Y Receptor	Cardiovascular Disease Cancer
Ticagrelor (AZD6140) is a reversible oral *P2Y12* receptor antagonist for the treatment of platelet aggregation.

HY-15283

Clopidogrel Maximum Cited Publications 30 Publications Verification Clopidogrelum	P2Y Receptor	Cardiovascular Disease Cancer
Clopidogrel is an orally active platelet inhibitor that targets *P2Y12* receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

HY-108660

PSB-0739 1 Publications Verification	P2Y Receptor	Cardiovascular Disease
PSB-0739 is a high-affinity potent, competitive, nonselective platelet **P2Y₁₂ receptor** antagonist with a K_i values of 24.9 nM. The P2Y₁₂ receptor plays a crucial role in platelet aggregation. Antithrombotic effect .

HY-15284

Prasugrel 1 Publications Verification PCR 4099	P2Y Receptor	Cardiovascular Disease
Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent *P2Y12* receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-118284

Vicagrel 1 Publications Verification	P2Y Receptor	Cardiovascular Disease
Vicagrel is a potent, safe and orally active antiplatelet agent, which works by irreversibly inhibiting **P2Y12 receptor**. Vicagrel can be used for the research of blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease .

HY-110322A

PPTN 4 Publications Verification	P2Y Receptor	Inflammation/Immunology
PPTN, a chemical probe, is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a K_B value of 434 pM. PPTN exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and immune activity .

HY-110322

PPTN hydrochloride 4 Publications Verification	P2Y Receptor	Inflammation/Immunology
PPTN hydrochloride is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a K_B value of 434 pM. PPTN hydrochloride exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and anti-immune activity .

HY-134353B

ADP-β-S trilithium Adenosine 5'-β-thiodiphosphate trilithium	P2Y Receptor NF-κB Interleukin Related Caspase	Neurological Disease Inflammation/Immunology Cancer
ADP-β-S (Adenosine 5'-(β-thiodiphosphate)) trilithium is a non-hydrolyzable ADP analog and a *P2Y12* receptor agonist. ADP-β-S trilithium activates the *P2Y12* receptor in microglia, thereby triggering downstream inflammatory signaling pathways. ADP-β-S trilithium activates P2Y purinergic receptors in rat pancreatic β cells and enhances glucose-induced insulin secretion. ADP-β-S trilithium can be used in the research of diseases such as inflammation and diabetes .

HY-15284A

Prasugrel hydrochloride 1 Publications Verification PCR 4099 hydrochloride	P2Y Receptor	Cardiovascular Disease
Prasugrel hydrochloride (PCR 4099 hydrochloride), a thienopyridine and proagent, inhibits platelet function. Prasugrel hydrochloride is an orally active and potent *P2Y12* receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15799

AZD1283	P2Y Receptor	Cardiovascular Disease
AZD1283 is a potent **P2Y₁₂ receptor antagonist with a binding IC₅₀ of 11 nM and a GTPγS IC₅₀** of 25 nM. AZD1283 has excellent antiplatelet aggregation potency. AZD1283 can be used to research thromboembolic disorders .

HY-108648

2-MeS-ADP trisodium 2-Methylthioadenosine diphosphate trisodium; 2-Methylthio-ADP trisodium	P2Y Receptor	Neurological Disease
2-Methylthioadenosine diphosphate trisodium is a potent purinergic P2Y receptors agonist, with EC₅₀s of 19, 6.2, and 5 nM for human P2Y13, mouse P2Y13 and human P2Y12, respectively. 2-Methylthioadenosine diphosphate trisodium has pEC₅₀s of 8.29 and 5.75 for human P2Y1 and rat P2Y6, respectively. 2-Methylthioadenosine diphosphate trisodium induces platelet aggregation and shape change, and inhibits cyclic AMP accumulation in platelets exposed to prostaglandin E1 .

HY-108648A

2-MeSADP 2-Methylthioadenosine diphosphate; 2-Methylthio-ADP	P2Y Receptor	Neurological Disease
2-MeSADP is a P2Y receptor agonist, with an EC₅₀ of 5 nM for human *P2Y12, EC₅₀* values of 19 nM and 13 nM for human P2Y13, and an EC₅₀ of 6.2 nM for mouse P2Y13. It shows slightly higher selectivity for *P2Y12* over human P2Y13. 2-MeSADP triggers increases in intracellular calcium levels, Gi-mediated cAMP inhibition, adenylate cyclase inhibition and downstream signal transduction. 2-MeSADP can be used in research related to glaucoma .

HY-109122

Selatogrel ACT-246475	P2Y Receptor	Cardiovascular Disease
Selatogrel (ACT-246475) is a reversible and selective *P2Y₁₂* receptor antagonist which inhibits platelet aggregation with an IC₅₀ of 8 nM. Selatogrel exhibits antithrombotic efficacy .

HY-15876

Clopidogrel thiolactone	Drug Metabolite P2Y Receptor	Cardiovascular Disease
Clopidogrel thiolactone is an important intermediate in the metabolism of Clopidogrel (HY-15283). Clopidogrel thiolactone has antiplatelet aggregatione effects. Clopidogrel is a **P2Y12 receptor** inhibitor that exerts antiplatelet effects .

HY-107867

(±)-Clopidogrel bisulfate	P2Y Receptor	Cardiovascular Disease Inflammation/Immunology
(±)-Clopidogrel bisulfate is a platelet **P2Y12 receptor** inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects .

HY-N0910

Notoginsenoside Ft1 1 Publications Verification	PI3K mTOR Akt Apoptosis p38 MAPK ERK Transmembrane Glycoprotein Glutathione Reductase (GR) Estrogen Receptor/ERR Calcium Channel Ferroptosis G protein-coupled Bile Acid Receptor 1 FXR	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Notoginsenoside Ft1 is an orally active bioactive saponin. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8 ⁺ T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca ²⁺ accumulation, reduces cAMP levels by activating a signaling network mediated through *P2Y₁₂* receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an FXR antagonist to combat obesity and insulin resistance .

HY-123669A

trans-R-138727	P2Y Receptor	Cardiovascular Disease
Trans-R-138727 is the trans isomer of R-138727 (HY-123669). R-138727 is the active metabolite of the antiplatelet agent Prasugrel (HY-15284). R-138727 is an irreversible inhibitor for the platelet receptor P2Y12, and inhibits ADP-induced platelet activation and aggregation .

HY-108656

MRS2365	P2Y Receptor Arrestin	Cardiovascular Disease
MRS2365 is a potent and selective **P2Y1 receptor (EC₅₀=0.4 nM) /[ ³⁵S]GTPγS binding/β-arrestin 2 recruitment agonist with an EC₅₀** of 0.4 nM. MRS2365 relieves mechanical allodynia and increases mechanical sensitivity. MRS2365 shows little agonist or antagonist activity at the P2Y12 or P2Y13 receptors .

HY-173447

8-BuS-AMP	NTPDase CD73	Cancer
8-BuS-AMP is a NTPDase1 inhibitor and a CD73/CD39 inhibitor, with an IC₅₀ of 35 μM and a K_i value of 0.292 μM against human NTPDase1; its K_i values against human CD73 and CD39 are 1.19 μM and 0.847 μM, respectively. 8-BuS-AMP binds to the substrate-binding pockets of NTPDase1 and CD73 to effectively block the conversion of ATP and AMP to adenosine, thereby enhancing the activation and proliferation of human peripheral T lymphocytes. 8-BuS-AMP possesses excellent enzymatic hydrolysis resistance and metabolic stability, resists hydrolysis by multiple NTPDase subtypes, and shows no activity against P2Y1 and P2Y12 receptors. 8-BuS-AMP can be used in purinergic signaling pathway and cancer-related studies .

HY-123669

R-138727	P2Y Receptor Drug Metabolite	Cardiovascular Disease
R-138727, the major active metabolite of Prasugrel (HY-15284), is a highly potent and selective irreversible antagonist of the P2Y12 receptor, with an IC₅₀ of 2.5 μM. R-138727 covalently binds to the P2Y12 receptor on the platelet surface, blocking adenosine diphosphate-mediated platelet activation and aggregation. R-138727 can be used to study stroke, cerebral infarction and neurological deficits.

HY-77734

AR-C133913XX	Drug Metabolite	Cardiovascular Disease
AR-C124910XX is a metabolite of Ticagrelor (HY-10064 ). Ticagrelor is a reversible oral *P2Y12* receptor antagonist, and can be used for study of platelet aggregation .

HY-137955

MRS 2211 sodium hydrate	P2Y Receptor	Cardiovascular Disease Others Neurological Disease
MRS 2211 sodium hydrate is a competitive P2Y13 receptor antagonist (pIC₅₀= 5.97). MRS 2211 sodium hydrate is highly selective to the P2Y13 receptor, showing more than 20-fold selectivity compared to the P2Y1 and P2Y12 receptors. MRS 2211 sodium hydrate can be used to further investigate the role of the P2Y13 receptor in different physiological and pathological processes, such as its function in blood cells, the nervous system and the immune system .

HY-10064S

Ticagrelor-d7 1 Publications Verification	Isotope-Labeled Compounds P2Y Receptor	Cardiovascular Disease Cancer
Ticagrelor-d₇ is the deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation .

HY-133781

cis-Clopidogrel-MP derivative Clopidogrel-MP-AM	Drug Metabolite	Others
cis-Clopidogrel-MP derivative (Clopidogrel-MP-AM) is a 3’-methoxyacetophenone derivative of Clopidogrel active metabolite . Clopidogrel is an orally active platelet inhibitor that targets P2Y12 receptor .

HY-15284S2

Prasugrel-d4 PCR 4099-d₄	P2Y Receptor	Cardiovascular Disease
Prasugrel-d₄ is the deuterium labeled Prasugrel . Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-123490

Regrelor disodium INS50589	P2Y Receptor	Inflammation/Immunology
Regrelor disodium (INS 50589) is a platelet *P2Y12* receptor antagonist. Regrelor disodium is a well-tolerated, reversible ADP competitive antagonist. Regrelor disodium inhibits cell proliferation. Regrelor disodium can be used in inflammation-related research .

HY-136501

MRS2395	P2Y Receptor	Cardiovascular Disease
MRS2395, an dipivaloyl derivative, is a potent *P2Y12* receptor antagonist. MRS2395 inhibits ADP-induced platelet activation with a K_i of 3.6 μM. MRS2395 inhibits cAMP induced by ADP in rat platelets in the presence of PGE1 with an IC₅₀ of 7 µM. MRS2395 enhances platelet dense granule release in response to TRAP-6 .

HY-111755

P2Y12 antagonist 2	P2Y Receptor	Cardiovascular Disease
P2Y12 antagonist 2 is a potent **P2Y₁₂ receptor** antagonist. P2Y12 antagonist 2 exhibits excellent antiplatelet aggregation potency with an IC₅₀ value of 2.94 μM as well as antithrombotic efficacy in a rat ferric chloride model. P2Y12 antagonist 2 shows a superior safety profile than Clopidogrel (HY-15283) in a rat tail-bleeding model. P2Y12 antagonist 2 can be used to research thromboembolic disorders .

HY-134353A

ADP-β-S trisodium Adenosine 5'-(β-thiodiphosphate) trisodium	Interleukin Related P2Y Receptor NF-κB Caspase	Neurological Disease Inflammation/Immunology Cancer
ADP-β-S (Adenosine 5'-(β-thiodiphosphate)) trilithium is a non-hydrolyzable ADP analog and a *P2Y12* receptor agonist. ADP-β-S trilithium activates the *P2Y12* receptor in microglia, thereby triggering downstream inflammatory signaling pathways. ADP-β-S trilithium activates P2Y purinergic receptors in rat pancreatic β cells and enhances glucose-induced insulin secretion. ADP-β-S trilithium can be used in the research of diseases such as inflammation and diabetes .

HY-148300

AR-C66096	P2Y Receptor	Cardiovascular Disease
AR-C66096 is a potent and selective antagonist of the Gi-coupled **P2Y12 receptor**. AR-C66096 suppresses platelet thrombus stability under physiological flow conditions. AR-C66096 inhibits ADP-induced aggregation in whole blood aggregometry. AR-C66096 can be used for antithrombotic research .

HY-137749A

MANT-dADP trisodium 2'-Deoxy-3'-MANT-ADP trisodium	Biochemical Assay Reagents	Others
MANT-dADP (trisodium) (2'-Deoxy-3'-MANT-ADP (trisodium)) is a fluorescent nucleotide derivative, with an emission maximum of 453 nm upon excitation at 350 nm. MANT-dADP (trisodium) can decrease inositol phoshate formation in CHO-K1 cells that express human purinergic P2Y₁₂ receptor. MANT-dADP (trisodium) can be studied in research on the interaction between cardiac troponin I and myofibrils .

HY-179133

HDB-1	P2Y Receptor PKA Raf MEK ERK	Inflammation/Immunology
HDB-1 is a selective inhibitor of the P2Y14 receptor (P2Y14R) with an IC₅₀ of 26 pM. HDB-1 shows no significant inhibition on P2Y1R, P2Y2R, P2Y4R, P2Y6R, and P2Y12R. HDB-1 blocks the activation of hepatic stellate cells (HSC) by inhibiting the PKA/Raf1/MEK/ERK signaling pathway mediated by P2Y14R, thereby alleviating the core pathological process of liver fibrosis. HDB-1 can be used for the study of liver fibrosis .

HY-163645

P2Y12 antagonist 1	P2Y Receptor	Cardiovascular Disease
P2Y12 antagonist 1 (compound 26) is a P2Y12 receptor antagonist with a Ki of 3.13 μM. P2Y12 antagonist 1 can be used to inhibit platelet aggregation and is a potential antithrombotic agent .

HY-174153

PSB-22219	P2Y Receptor	Neurological Disease Inflammation/Immunology
PSB-22219 is a highly selective non-nucleotidic ligand acting on **P2Y₁₂ receptors (K_D*=4.57 nM). PSB-22219 is promising for research of P2Y₁₂* receptor-associated neuroinflammation .

HY-111064

BX 667	P2Y Receptor	Cardiovascular Disease
BX 667 is an orally active reversible **P2Y(12) receptor** antagonist. BX 667 attenuates thrombosis .

HY-110265

SAR216471 hydrochloride	P2Y Receptor	Inflammation/Immunology
SAR216471 hydrochloride is a **P2Y12 receptor** antagonist. SAR216471 hydrochloride has antiplatelet and antithrombotic activities in vivo .

HY-172181

NSC380324	P2Y Receptor	Cardiovascular Disease
NSC380324 is a *P2Y₁₂* receptor antagonist, possessing antiplatelet activity, and can be utilized in research on atherosclerotic cardiovascular diseases .

HY-172417

Becondogrel 2-Oxoclopidogrel	P2Y Receptor	Cardiovascular Disease
Becondogrel (2-Oxoclopidogrel) is the metabolite of Clopidogrel (HY-15283). Becondogrel irreversibly inhibits **P2Y12 receptor**, thereby inhibiting platelet aggregation and thrombosis .

HY-10064R

Ticagrelor (Standard) AZD6140 (Standard); AR-C 126532XX (Standard)	Reference Standards P2Y Receptor	Cardiovascular Disease Cancer
Ticagrelor (Standard) is the analytical standard of Ticagrelor. This product is intended for research and analytical applications. Ticagrelor (AZD6140) is a reversible oral *P2Y12* receptor antagonist for the treatment of platelet aggregation.

HY-15284B

Prasugrel (Maleic acid) PCR 4099 (Maleic acid)	P2Y Receptor	Cardiovascular Disease
Prasugrel (PCR 4099) Maleic acid is a thienopyridine and proagent, inhibits platelet function. Prasugrel Maleic acid is an orally active and potent *P2Y12* receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-10064S1

Ticagrelor-d4 AZD6140-d₄; AR-C 126532XX-d₄	Isotope-Labeled Compounds P2Y Receptor	Cardiovascular Disease Cancer
Ticagrelor-d₄ (AZD6140-d₄) is deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral *P2Y12* receptor antagonist for the treatment of platelet aggregation.

HY-119085

ACT-281959	P2Y Receptor	Cardiovascular Disease
ACT-281959 is an orally active prodrug of Selatogrel (HY-109122), a *P2Y12* receptor antagonist. ACT-281959 can inhibit platelet aggregation and can be used for the research of cardiovascular disease .

HY-136142

Prasugrel chloride impurity	Drug Metabolite	Others
Prasugrel chloride impurity is a catp impurity of Prasugrel, exacted from patent US20130345428A1, line 0053. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284S1

Prasugrel-d3 PCR 4099-d₃	P2Y Receptor	Cardiovascular Disease
Prasugrel-d₃ is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284S

Prasugrel-d5 PCR 4099-d₅	Isotope-Labeled Compounds P2Y Receptor	Cardiovascular Disease
Prasugrel-d₅ is deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and prodrug, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284AR

Prasugrel hydrochloride (Standard) PCR 4099 hydrochloride (Standard)	Reference Standards P2Y Receptor	Cardiovascular Disease
Prasugrel (hydrochloride) (Standard) is the analytical standard of Prasugrel (hydrochloride). This product is intended for research and analytical applications. Prasugrel hydrochloride (PCR 4099 hydrochloride), a thienopyridine and proagent, inhibits platelet function. Prasugrel hydrochloride is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15283R

Clopidogrel (Standard) Clopidogrelum (Standard)	Reference Standards P2Y Receptor	Cardiovascular Disease Cancer
Clopidogrel (Standard) is the analytical standard of Clopidogrel. This product is intended for research and analytical applications. Clopidogrel is an orally active platelet inhibitor that targets *P2Y12* receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

HY-15284R

Prasugrel (Standard) PCR 4099 (Standard)	Reference Standards P2Y Receptor	Cardiovascular Disease
Prasugrel (Standard) is the analytical standard of Prasugrel. This product is intended for research and analytical applications. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent *P2Y12* receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284S3

Prasugrel-13C6 PCR 4099-¹³C₆	Isotope-Labeled Compounds P2Y Receptor	Cardiovascular Disease
Prasugrel-13C6 is a deuterated labeled Prasugrel . Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent *P2Y12* receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-W686186

Prasugrel hydroxy thiolactone	Drug Metabolite P2Y Receptor	Cardiovascular Disease
Prasugrel hydroxy thiolactone (compound M18) is a metabolite of Prasugrel (HY-15284). Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits Adenosine 5'-diphosphate (ADP, HY-W010918)-induced platelet aggregation .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0910

Notoginsenoside Ft1 1 Publications Verification	Triterpenes Structural Classification Panax notoginseng (Burkill) F. H. Chen ex C. H. Chow Classification of Application Fields Terpenoids Other Diseases Plants Disease Research Fields Araliaceae Source Classification	PI3K mTOR Akt Apoptosis p38 MAPK ERK Transmembrane Glycoprotein Glutathione Reductase (GR) Estrogen Receptor/ERR Calcium Channel Ferroptosis G protein-coupled Bile Acid Receptor 1 FXR
Notoginsenoside Ft1 is an orally active bioactive saponin. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8 ⁺ T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca ²⁺ accumulation, reduces cAMP levels by activating a signaling network mediated through *P2Y₁₂* receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an FXR antagonist to combat obesity and insulin resistance .

Cat. No.	Product Name	Chemical Structure

HY-10064S

Ticagrelor-d7 1 Publications Verification
Ticagrelor-d₇ is the deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation .

HY-15284S2

Prasugrel-d4
Prasugrel-d₄ is the deuterium labeled Prasugrel . Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-10064S1

Ticagrelor-d4
Ticagrelor-d₄ (AZD6140-d₄) is deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral *P2Y12* receptor antagonist for the treatment of platelet aggregation.

HY-15284S1

Prasugrel-d3
Prasugrel-d₃ is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284S

Prasugrel-d5
Prasugrel-d₅ is deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and prodrug, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284S3

Prasugrel-13C6
Prasugrel-13C6 is a deuterated labeled Prasugrel . Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent *P2Y12* receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-107867S1

(Rac)-Clopidogrel hydrogen-d9 sulfate

(Rac)-Clopidogrel hydrogen-d₉ sulfate is the deuterium labeled (±)-Clopidogrel (bisulfate) (HY-107867). (±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects .

HY-107867S2

Clopidogrel-13C,d3 sulfate

Clopidogrel- ¹³C,d₃ sulfate is the deuterium and ¹³C-labeled (±)-Clopidogrel (bisulfate) (HY-107867). (±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects .

HY-15283AS1

(±)-Clopidogrel-d4

(±)-Clopidogrel-d₄ ((±)-Clopidogrelum-d₄) is the deuterium labeled (±)-Clopidogrel (HY-107867). (±)-Clopidogrel is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel has anti-inflammatory effects .

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P87002

	P2Y12 Antibody (YA6695) 1 Publications Verification ADP glucose receptor antibody; ADP-glucose receptor antibody; ADPG R antibody; ADPG-R antibody; ADPGR antibody; BDPLT8 antibody; G protein coupled receptor SP1999 antibody; Gi coupled ADP receptor HORK 3 antibody; Gi coupled ADP receptor HORK3 antibody; HORK 3 antibody; ADP glucose receptor antibody; ADP-glucose receptor antibody; ADPG R antibody; ADPG-R antibody; ADPGR antibody; BDPLT8 antibody; G protein coupled receptor SP1999 antibody; Gi coupled ADP receptor HORK 3 antibody; Gi coupled ADP receptor HORK3 antibody; HORK 3 antibody; HORK3 antibody; P2RY 12 antibody; P2RY12 antibody; P2T(AC) antibody; P2Y 12 antibody; P2Y purinoceptor 12 antibody; P2Y(12)R antibody; P2Y(AC) antibody; P2Y(ADP) antibody; P2Y(cyc) antibody; P2Y12 antibody; P2Y12 platelet ADP receptor antibody; P2Y12_HUMAN antibody; Platelet ADP receptor antibody; Purinergic receptor P2RY12 antibody; Purinergic receptor P2Y G protein coupled 12 antibody; Purinergic receptor P2Y12 antibody; Putative G protein coupled receptor antibody; SP 1999 antibody; SP1999 antibody;	IHC-F, IHC-P	Mouse, Rat
	P2Y12 Antibody (YA6695) is a Rat -derived and non-conjugated IgG1 monoclonal antibody, targeting to P2Y12.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks